Last reviewed · How we verify
Topical Adapalene Gel 0.1%
Adapalene is a third-generation retinoid that binds to retinoic acid receptors to normalize skin cell differentiation and reduce inflammation in acne.
Adapalene is a third-generation retinoid that binds to retinoic acid receptors to normalize skin cell differentiation and reduce inflammation in acne. Used for Acne vulgaris.
At a glance
| Generic name | Topical Adapalene Gel 0.1% |
|---|---|
| Sponsor | University of Louisville |
| Drug class | Retinoid |
| Target | Retinoic acid receptor gamma (RARγ) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Adapalene selectively activates retinoic acid receptor gamma (RARγ) and other retinoid receptors, promoting keratinocyte differentiation and reducing comedone formation. It also exhibits anti-inflammatory properties by modulating cytokine production and reducing sebum production, making it effective for treating acne vulgaris.
Approved indications
- Acne vulgaris
Common side effects
- Erythema
- Scaling
- Dryness
- Pruritus
- Photosensitivity
Key clinical trials
- Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study (PHASE2)
- Auricular Acupressure Combined With Adapalene for the Treatment of Acne Vulgaris (NA)
- Experience With Topical Acne Treatment (EARLY_PHASE1)
- Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgaris (PHASE4)
- Comparison of Effectiveness of Topical Retinoids Versus Liquid Nitrogen in Treatment of Plantar Warts(Viral Infection) (PHASE4)
- Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris (PHASE3)
- MC RCT - BPO vs Adapalene (PHASE3)
- Long-term Study of Efficacy/Safety of Adapalene/Benzoyl Peroxide Topical Gel in Acne Vulgaris Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical Adapalene Gel 0.1% CI brief — competitive landscape report
- Topical Adapalene Gel 0.1% updates RSS · CI watch RSS
- University of Louisville portfolio CI